Medical & Commercial

Featured

The Fit-for-Purpose Gap: What RWD Still Gets Wrong

In this session, industry experts Dr. Radek Wasiak and Isabella Even-Chen break down the critical "Fit-for-Purpose Gap"—the misstep of assuming a single, generalized dataset can satisfy every study design, regulatory requirement, or health economics endpoint.

Highlight

Medical & Commercial

The Fit-for-Purpose Gap: What RWD Still Gets Wrong

World Orphan Drug Congress Europe: October 26-28 at the RAI Convention Centre in Amsterdam

Getting COA strategy right from the start: Early endpoint decisions that strengthen evidence and reduce risk

A Farewell Message From Patti Peeples, HealthEconomics.Com Founder

Supplier Spotlight: MArS

Supplier Spotlight: GPI

Delivering Real World Data-Driven Insights: An Executive Interview with Wendy Shusko and Jason Drenning

Podcast Q&A: How Literature Review Automation and Efficient Processes Streamline RWE HEOR Studies?

What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?

The private health insurances as the entrance into German market access - is this true, Dr. Bastian Biermann?

How can a company derive the optimal price for their medical product, Dr. Renato, Dellamano?

How do innovations reach patients in German hospitals, Dr. Sebastian Casu?

How does hospital funding work in Germany, Willi Wollner?

Prof. Dr. Juergen Wasem - What happens, when negotiations fail?

Dr. Michael Zuercher - Commerical attractiveness of the Swiss health care market - success starts with market access.

Aging Webinar Series 2021

Why Linked Healthcare Data is the New Research Standard

Prof. Peter Zweifel & Door Vonk - Digital Innovation - from theory into practice!

Supplier Spotlight: Actu Real

Health economic analysis of distributional equity impacts - a call to action

Prospective Oncology Real-World Data Capture

Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.

Supplier Spotlight: Veradigm

Preparing a Successful ICER Strategy: Lessons from the Frontlines

Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?

The future of market access: a new model for the 'next normal'

Remo Christen - Early paid access in Switzerland - Switzerland, wonderland??

Cutting Edge Conversation: Biotech Market Access

Getting COA strategy right from the start: Early endpoint decisions that strengthen evidence and reduce risk

The Fit-for-Purpose Gap: What RWD Still Gets Wrong

Filling the Gap: Integrating Patient-Generated Data into Real-World Evidence

Closing Gaps in Care: Health Equity and the Inflation Reduction Act - A Cutting Edge Conversation

Network meta-analysis and its role in evidence-based decision-making

Sustainable Science: Transforming Pharma-Supplier Partnerships

Addressing Orphan and Rare Diseases - A Cutting Edge Conversation

Joint Clinical Assessment 2025: Pioneering Pathways for Oncology, Advanced Therapies & Rare Diseases

RWE reality check: Routine patient health records and regulatory requirements

"S" Stands for Systematic: Demystifying the Systematic Literature Review

Survival Analysis for Immature Data: A Review of Techniques and Lessons Learned

Market Access - Transforming BioTech Commercial Decisions?

The Scientific and Operational Elegance of Study Replication with Real-World EHR Data: A Vitiligo and Alopecia Example

Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping

Insights from the 2024 Salary Survey Report by HealthEconomics.com

Beyond Accelerated Approvals: External Control Arms

Delphi Panels: What Are They Good For?

Unraveling European Animal Welfare Legislation for Biotech & Pharma

Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches

Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management

Understanding Animal Welfare Best Practices in Asia Pacific for Biotech & Pharma

Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults

Navigating Animal Welfare Legislation in North America: Insights for Biotech & Pharma

Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters

EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025

Cell & Gene Therapies - Beginning with the End in Mind

Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases

Integrating Patient Engagement and Trainee Development in Pre-Clinical Research

Pharma can target ultra-rare conditions ‚Äî the next step is financing them

Transforming Healthcare Using Big Data and Remote Monitoring

Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation

Minimizing the Impact of Cross-Cultural Differences in COA Translations

Synthesise RWE and AI. Transform patient-driven healthcare

Endpoints at #DIA23

Tracking and Measuring Market Access Performance

Certified Corporate Wellness Specialist(CCWS): Is It For Me?

L7|LIVE SF - Tuesday, June 13th, 2023

Transforming clinical research: Scaling real-world data across diseases with expert-led AI

Connected communities: Advancing population health through data and emerging technology

Improving Patient Outcomes: AI-Based Phenotyping for Diagnosis, Treatment, and Clinical Trials

The reimagined hospital: How health systems are keeping up with new tech

Clinical Trial Innovation: How Healthcare Technology is Evolving

How to assess the quality of AI output when structuring unstructured medical data

Driving value from healthcare data: How integrated cloud-based data is foundational to drive enterprise change

Advancing identity data management for digital engagement: How leading organizations are doing it

How Digital Health Can Empower Cancer Patients

Keeping up with demands for healthcare outside of the hospital: Critical ways tech supports the distributed care model

Closing the gaps of getting data to make decisions

Patient Data: Opportunities for Rare Diseases, Cell and Gene Therapies, and Oncology

Medicare Part D: Price Negotiation Panel Discussion

Notice of Pre-Application Webinar for RFA-AG-24-009, "Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional)"